Here we report that VSL#3 administration is effective in preventing development of an acute colitis induced by TNBS and found that protection correlates with a robust attenuation of inflammation as measured by assessing the colitis macroscopic score, neutrophil infiltration and the mRNA levels of TNFα, IL-1β, IL-6 and IFNγ. This evidence concerns the gene IL6 and colitis.